Fig. 3From: An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocolA schematic design of the clinical study. The examination for safety ends 14 days after the ZOL injection but the patient are followed up for the efficacy until day 28 and every 4 weeks thereafter. The patient can repeatedly receive ZOL in the pleural cavity at a 4-weeks intervalBack to article page